Literature DB >> 32077908

Glaucoma Care of Prison Inmates at an Academic Hospital.

Levi N Kanu1, Inae Jang1, Daniel J Oh1, Manpreet S Tiwana1, Amy A Mehta1, Mark S Dikopf1, Thasarat S Vajaranant1, Ahmad A Aref1, Deepak P Edward1,2.   

Abstract

Importance: Glaucoma care for prison inmates is underrepresented in the literature even though managing the treatment of such patients may provide unique challenges.
Objectives: To evaluate the glaucoma profile of prison inmates treated at an academic ophthalmology center and to report on the medical and surgical management and follow-up metrics. Design, Setting, and Participants: This retrospective cohort study assessed data from 82 incarcerated patients treated at the glaucoma clinic, an academic referral center at the University of Illinois at Chicago, between January 2013 and December 2017. Main Outcomes and Measures: Diagnosis, glaucoma severity, medical and surgical interventions, and patient-reported medication adherence were recorded for each visit. Recommended and actual follow-up times were recorded and compared. Data analyses were conducted from January 2013 to December 2018.
Results: In total, 82 patients (161 eyes) had 375 visits during the study period. All patients were male and ranged from 20 to 75 years of age (mean [SD] age, 50.8 [11.9] years). Most participants were black patients (65 [79.3%]). The most common diagnoses were primary open-angle glaucoma (POAG; 53 eyes [32.9%]) and POAG suspect (52 eyes [32.3%]). Glaucoma severity ranged from mild (25 of 77 eyes [32.5%]) to advanced (41 of 77 eyes [53.2%]). Overall, 59 patients (73.2%) were treated medically with up to 4 topical agents (40.0%). Of those treated, 70.0% of patients (95% CI, 57.7%-81.2%) reported medication nonadherence during at least 1 visit. Medication nonadherence was more common among those taking 4 different topical medications (21 of 24 [87.5%]) compared with others taking fewer medications (20 of 35 [57.1%]), for a difference of 30.4% (95% CI, 7.0%-53.6%; P = .02), and among those with advanced disease (22 of 26 [84.6%]) compared with glaucoma suspect (6 of 13 [46.2%]), for a difference of 38.4% (95% CI, 9.3%-67.5%; P = .02). Nineteen office procedures, including laser peripheral iridotomy and laser trabeculoplasty, were performed on 14 eyes. Seventeen incisional glaucoma procedures were performed on 15 eyes, including glaucoma drainage device implant (11 procedures [64.7%]) and trabeculectomy (3 procedures [17.6%]). Only 26.6% of return office visits (95% CI, 21.3%-32.3%) occurred within the recommended follow-up time frame. Furthermore, 93 patients (34.8%; 95% CI, 28.2%-40.0%) were seen more than 1 month after the recommended follow-up. Conclusions and Relevance: Despite incarceration in prison, where medication administration and appointment attendance are theoretically controlled, the results of this study suggested that substantial medication and follow-up nonadherence exists among inmates.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32077908      PMCID: PMC7042904          DOI: 10.1001/jamaophthalmol.2020.0001

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  38 in total

1.  Patterns of Glaucoma Medication Adherence over Four Years of Follow-Up.

Authors:  Paula Anne Newman-Casey; Taylor Blachley; Paul P Lee; Michele Heisler; Karen B Farris; Joshua D Stein
Journal:  Ophthalmology       Date:  2015-08-25       Impact factor: 12.079

2.  Practice preferences for glaucoma surgery: a survey of the American Glaucoma Society in 2008.

Authors:  Manishi A Desai; Steven J Gedde; William J Feuer; Wei Shi; Philip P Chen; Richard K Parrish
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2011 May-Jun

3.  Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up.

Authors:  Steven J Gedde; Joyce C Schiffman; William J Feuer; Leon W Herndon; James D Brandt; Donald L Budenz
Journal:  Am J Ophthalmol       Date:  2012-01-15       Impact factor: 5.258

Review 4.  Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review.

Authors:  Christine M G Olthoff; Jan S A G Schouten; Bart W van de Borne; Carroll A B Webers
Journal:  Ophthalmology       Date:  2005-06       Impact factor: 12.079

5.  Risk factors for late presentation in chronic glaucoma.

Authors:  S Fraser; C Bunce; R Wormald
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-09       Impact factor: 4.799

Review 6.  HIV risk inside U.S. prisons: a systematic review of risk reduction interventions conducted in U.S. prisons.

Authors:  Pamela Valera; Yvonne Chang; Zi Lian
Journal:  AIDS Care       Date:  2016-12-27

7.  School disengagement as a predictor of dropout, delinquency, and problem substance use during adolescence and early adulthood.

Authors:  Kimberly L Henry; Kelly E Knight; Terence P Thornberry
Journal:  J Youth Adolesc       Date:  2011-04-27

8.  Primary Open-Angle Glaucoma Preferred Practice Pattern(®) Guidelines.

Authors:  Bruce E Prum; Lisa F Rosenberg; Steven J Gedde; Steven L Mansberger; Joshua D Stein; Sayoko E Moroi; Leon W Herndon; Michele C Lim; Ruth D Williams
Journal:  Ophthalmology       Date:  2015-11-12       Impact factor: 12.079

9.  Personalized behavior change program for glaucoma patients with poor adherence: a pilot interventional cohort study with a pre-post design.

Authors:  Paula Anne Newman-Casey; Leslie M Niziol; Chamisa K Mackenzie; Kenneth Resnicow; Paul P Lee; David C Musch; Michele Heisler
Journal:  Pilot Feasibility Stud       Date:  2018-07-23

10.  Patient race, reported problems in using glaucoma medications, and adherence.

Authors:  Betsy Sleath; Susan J Blalock; David Covert; Asheley Cockrell Skinner; Kelly W Muir; Alan L Robin
Journal:  ISRN Ophthalmol       Date:  2012-10-15
View more
  1 in total

1.  Glaucoma Care of Incarcerated Patients at an Academic Institution: A Case-Control Study.

Authors:  Levi N Kanu; Daniel J Oh; Inae Jang; Michael Henry; Amy A Mehta; Mark S Dikopf; Thasarat S Vajaranant; Ahmad A Aref; Deepak P Edward
Journal:  J Curr Ophthalmol       Date:  2021-07-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.